BerGenBio Appoints Olav Hellebø as CEO
BerGenBio ASA (OSE: BGBIO) has appointed Olav Hellebø as CEO, effective November 21, 2024. Hellebø brings 30 years of pharmaceutical and biotechnology industry experience, including roles at Cytovation ASA, Antev , ReNeuron Group PLC, and Clavis Pharma ASA. He has also held leadership positions at UCB-Celltech, Novartis UK, and Schering-Plough. The company is developing selective AXL kinase inhibitors, with its candidate drug bemcentinib in clinical trials for non-squamous non-small cell lung cancer patients with STK11 gene mutations.
BerGenBio ASA (OSE: BGBIO) ha nominato Olav Hellebø come CEO, con effetto dal 21 novembre 2024. Hellebø porta con sé 30 anni di esperienza nel settore farmaceutico e biotecnologico, includendo ruoli in Cytovation ASA, Antev, ReNeuron Group PLC e Clavis Pharma ASA. Ha inoltre ricoperto posizioni di leadership in UCB-Celltech, Novartis UK e Schering-Plough. L'azienda sta sviluppando inibitori selettivi della chinasi AXL, con il suo farmaco candidato bemcentinib attualmente in sperimentazione clinica per pazienti con cancro polmonare non a piccole cellule non squamoso che presentano mutazioni del gene STK11.
BerGenBio ASA (OSE: BGBIO) ha nombrado a Olav Hellebø como CEO, con efecto desde el 21 de noviembre de 2024. Hellebø aporta 30 años de experiencia en la industria farmacéutica y biotecnológica, incluyendo roles en Cytovation ASA, Antev, ReNeuron Group PLC y Clavis Pharma ASA. También ha ocupado posiciones de liderazgo en UCB-Celltech, Novartis UK y Schering-Plough. La compañía está desarrollando inhibidores selectivos de la quinasa AXL, con su fármaco candidato bemcentinib en ensayos clínicos para pacientes con cáncer de pulmón no microcítico y no escamoso que tienen mutaciones en el gen STK11.
BerGenBio ASA (OSE: BGBIO)는 Olav Hellebø를 2024년 11월 21일부터 CEO로 임명했습니다. Hellebø는 Cytovation ASA, Antev, ReNeuron Group PLC 및 Clavis Pharma ASA에서의 역할을 포함하여 제약 및 생명공학 산업에서 30년의 경험을 가지고 있습니다. 그는 또한 UCB-Celltech, Novartis UK 및 Schering-Plough에서 리더십 직책을 맡아왔습니다. 이 회사는 선택적 AXL 키나제 억제제를 개발하고 있으며, 후보 약물인 bemcentinib는 STK11 유전자 변이를 가진 비편평 비소세포 폐암 환자를 위한 임상 시험을 진행 중입니다.
BerGenBio ASA (OSE: BGBIO) a nommé Olav Hellebø en tant que PDG, à compter du 21 novembre 2024. Hellebø compte 30 ans d'expérience dans l'industrie pharmaceutique et biotechnologique, incluant des rôles chez Cytovation ASA, Antev, ReNeuron Group PLC et Clavis Pharma ASA. Il a également occupé des postes de direction chez UCB-Celltech, Novartis UK et Schering-Plough. L'entreprise développe des inhibiteurs sélectifs de la kinase AXL, avec son médicament candidat bemcentinib actuellement en essais cliniques pour des patients atteints de cancer du poumon non à petites cellules non squameux présentant des mutations du gène STK11.
BerGenBio ASA (OSE: BGBIO) hat Olav Hellebø mit Wirkung zum 21. November 2024 zum CEO ernannt. Hellebø bringt 30 Jahre Erfahrung in der Pharma- und Biotechnologiebranche mit, einschließlich Positionen bei Cytovation ASA, Antev, ReNeuron Group PLC und Clavis Pharma ASA. Er hat außerdem Führungspositionen bei UCB-Celltech, Novartis UK und Schering-Plough innegehabt. Das Unternehmen entwickelt selektive AXL-Kinase-Inhibitoren, wobei das Kandidatenmedikament bemcentinib derzeit klinischen Studien für Patienten mit nicht-squamösem, nicht-kleinzelligen Lungenkrebs und STK11-Genmutationen unterzogen wird.
- Appointment of experienced CEO with 30 years of industry expertise
- New CEO has previous experience leading biotech companies and securing partnerships
- Strong background in capital raising and pharmaceutical development
- None.
Mr. Hellebø brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, Antev Ltd, specializing in urology and oncology treatments. Prior to this, Mr. Hellebø's experience includes the role as CEO of ReNeuron Group PLC, a
"BerGenBio is at the forefront of exploring highly selective AXL inhibition as a therapeutic enhancement for the large number of patients with non-squamous non-small cell lung cancer with mutations in the STK11 gene. I am thrilled to join the company and look forward to collaborating with the board and team to advance the candidate drug, bemcentinib, through the next stages of clinical development and to take BerGenBio to the next phase", said Olav Hellebø.
"Mr. Hellebø brings a wealth of experience as a leader in pharmaceutical and biotechnology companies, with a strong track record of success. His extensive expertise in leading biotech companies, raising capital, and securing partnership deals makes him exceptionally well-suited to guide BerGenBio and to execute on our focused strategy to study STK11m NSCLC patients in our on-going Ph1b/2a BGBC016 trial", said Chairman of the Board, Anders Tullgren.
Contacts
Anders Tullgren, Chair of the Board, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Jan Lilleby, Media Relations, BerGenBio ASA
jl@lillebyfrisch.no
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-appoints-olav-hellebo-as-ceo,c4069475
View original content:https://www.prnewswire.com/news-releases/bergenbio-appoints-olav-hellebo-as-ceo-302312059.html
SOURCE BerGenBio ASA
FAQ
When will Olav Hellebø start as CEO of BerGenBio (OSE: BGBIO)?
What is BerGenBio's (OSE: BGBIO) main drug candidate?
What is Olav Hellebø's previous experience before joining BerGenBio (OSE: BGBIO)?
